Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021
06 déc. 2021 01h00 HE
|
Molecular Partners
First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical...
Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML
03 déc. 2021 01h00 HE
|
Molecular Partners
Research collaboration with leading acute myeloid leukemia (AML) experts, Professor Ochsenbein and Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital,...
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
30 nov. 2021 01h00 HE
|
Molecular Partners
Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concernTesting on the full Omicron variant has initiated, with...
Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference
24 nov. 2021 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
16 nov. 2021 01h00 HE
|
Molecular Partners
Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized...
Molecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 Clinical Trial
04 nov. 2021 02h00 HE
|
Molecular Partners
Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technologyPreclinical data support potential to deliver tumor-localized immune...
Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum
28 oct. 2021 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference
20 oct. 2021 01h00 HE
|
Molecular Partners
Ensovibep is shown in vitro to maintain inhibition against all variants of concern known to dateThe Company is also presenting a Trial in Progress poster on the EMPATHY clinical trial at the...
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
03 sept. 2021 16h05 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein...
Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021
26 août 2021 01h00 HE
|
Molecular Partners
-- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 ...